AKT and cancer-Is it all mTOR?

Neal Rosen, Qing Bai She

Research output: Contribution to journalShort surveypeer-review

56 Scopus citations

Abstract

AKT, a key regulator of cell proliferation and survival, is commonly dysregulated in human cancers. Activated AKT kinase is oncogenic and required for tumorigenesis in PTEN-deficient animals. However, the importance of AKT in mediating transformation by other oncogenes and which of its targets are necessary for this process are poorly understood. In this issue of Cancer Cell, Skeen et al. show that AKT is required for transformation by mutant H-Ras and for experimental skin carcinogenesis. Moreover, the effects of AKT are mediated predominantly or solely via mTORC1. This suggests that AKT or mTOR inhibitors will be useful treatments for many cancers.

Original languageEnglish
Pages (from-to)254-256
Number of pages3
JournalCancer Cell
Volume10
Issue number4
DOIs
StatePublished - Oct 2006

Funding

FundersFunder number
National Childhood Cancer Registry – National Cancer InstituteR01CA175105

    ASJC Scopus subject areas

    • Oncology
    • Cell Biology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'AKT and cancer-Is it all mTOR?'. Together they form a unique fingerprint.

    Cite this